Introduction {#mjw051s1}
============

The E26 transformation-specific (ETS) transcription factors are recognized as having an 85-amino acid DNA-binding domain---the ETS domain---that binds to the DNA sequence 5′-GGA(A/T)-3′, and are evolutionarily conserved throughout the metazoa ([@mjw051C59]). The ETS family has 28 members found in human and 27 members in mice, with human ETV7/TEL2 having no mouse orthologue ([@mjw051C16]; [@mjw051C24]). The ETS factors are grouped into 12 subfamilies according to the degree of similarity in their structures. Some subfamilies have only one member such as GABPA, SPDEF, and ETV2, while most have 2−3 members within the subfamily ([@mjw051C22]; [@mjw051C24]). The ETS factors are mostly involved in crucial biological processes such as development, differentiation, angiogenesis, growth, proliferation, senescence, and cell death ([@mjw051C49]). Unsurprisingly, many ETS transcription factors are implicated in the emergence and progression of cancer ([@mjw051C57]; [@mjw051C26]). Aside from their roles in malignancy, the ETS factors are also involved in cellular homoeostasis and immune regulation ([@mjw051C18]; [@mjw051C20]; [@mjw051C35]).

The E74-like factor (ELF) subfamily members can regulate immune responses and the development of immune-related cells ([@mjw051C75]; [@mjw051C11]). The members of this subgroup are ELF1, ELF2/NERF, and ELF4/MEF. ELF3 and ELF5 do not belong to the ELF subfamily, but rather belong to the epithelium-specific ETS (ESE) subfamily along with ESE-3/EHF, and are also known as ESE-1 and ESE-2, respectively. The ESE factors contain a pointed domain ([@mjw051C15]; [@mjw051C50]), which is not possessed by members of the ELF subfamily. ELF1, the founding member of the ELF family, is suggested to have important regulatory roles in erythroid maturation and the development of natural killer (NK), NK-T, and T cells ([@mjw051C74]; [@mjw051C9]; [@mjw051C11]). ELF2/NERF ([@mjw051C48]) has been implicated in the processes of invasion and metastasis, as well as in blood vessel development ([@mjw051C21]; [@mjw051C79]).

General features of ELF4 {#mjw051s2}
========================

Twenty years ago, a new member of the ETS family of transcription factors was discovered. The gene was cloned from a human megakaryocytic cell line. It has some structural similarity with the human *ELF-1* gene, and was named 'myeloid elf-1-like factor' (MEF) ([@mjw051C46]). There is 94% homology in the ETS region between MEF and ELF-1, making MEF a member of the ELF subfamily of ETS factors, and has been designated as 'ELF4'. Despite the high homology of the DNA-binding domain between ELF-1 and ELF-4, they do not transactivate the same genes ([@mjw051C46]), and in fact, they have an overall similarity of only 46% ([@mjw051C3]). ELF4, which is located in chromosome Xq26, was previously reported to be highly expressed in peripheral blood and present in all major tissues except the brain ([@mjw051C46]; [@mjw051C3]). Recent and more advanced methods of analyses have refined our knowledge on the gene expression pattern of *ELF4*. The extremely useful information presented in http://biogps.org/gene/2000 confirmed that human *ELF4* has a high expression in whole blood. It is also detected in the brain tissues, albeit at comparatively low level. Moreover, human *ELF4* is highly expressed in a variety of hematopoietic cells, such as NK cells, myeloid cells, T cells, and monocytes, and is moderately expressed in lung, placenta, thymus, and bone marrow. Mouse *Elf4* gene is highly expressed in mast cells, follicular B cells, lymph nodes, bone marrow, and pancreas (http://biogps.org/gene/2000). The high expression level of *ELF4* in cells of hematopoietic lineage suggests a role of ELF4 in immunity and in blood cell disorders.

The *ELF4* gene encodes a 663-amino acid protein that is composed of an activation domain at the N-terminal region, an ETS domain that binds to DNA consensus sequence, a serine/threonine-rich region, and a proline-rich region ([@mjw051C46]; [@mjw051C65]) (Figure [1](#mjw051F1){ref-type="fig"}A). It contains two nuclear localization signals at 173−183 and 196−202 amino acids, is mostly nuclear localizing, and can undergo ubiquitination and degradation in the nucleus ([@mjw051C65], [@mjw051C64]; [@mjw051C78]). ELF4 is phosphorylated at the C-terminal region, mostly at the serine and threonine residues from 641−657 amino acids ([@mjw051C45]; [@mjw051C37]) (Figure [1](#mjw051F1){ref-type="fig"}A). ELF4 can interact with various proteins at either the N-terminal or C-terminal region (Figure [1](#mjw051F1){ref-type="fig"}B) as discussed below. *Elf4* knockout (*Elf4*^*--/--*^) mice have no neonatal defects and develop normally, indicating that ELF4 does not play an essential role in embryonic development and that other ETS members may be able to compensate for its absence. However, *Elf4*^*--/--*^ mice have deficiencies in NK, NK-T, and T cell functions and impaired expansion of central and effector memory T cells to recall responses ([@mjw051C30]; [@mjw051C41]). This review aims to take stock of what is known about ELF4, especially in terms of how it is regulated and what biological processes and factors it regulates. The genes that are regulated by ELF4 are listed in Table [1](#mjw051TB1){ref-type="table"}, and the transcriptional and post-translational regulations of ELF4 are listed in Table [2](#mjw051TB2){ref-type="table"}. Despite the many facets of ELF4 being uncovered over the years, much more remain unknown, and it is hoped that the past lessons will provide a sound basis for future discoveries. Table 1Genes regulated by ELF4.GenesFunctionsEffect of ELF4References*GM-CSF*Growth factor, immunityActivation[@mjw051C46]*IL-3*Growth factor, immunityActivation[@mjw051C46]*LYZ*Antibacterial, immunityActivation[@mjw051C25]*DEFB4A*Antimicrobial, immunityActivation[@mjw051C39]*IL-8*Chemokine, immunityActivation, repression[@mjw051C56], [@mjw051C23]*PRF1*Cytolytic, immunityActivation[@mjw051C30]*IFNB1*Cytokine, immunityActivation[@mjw051C78]*IFNA*Cytokine, immunityActivation[@mjw051C78]*Klf2*Transcription factor, developmentActivation[@mjw051C76]*Klf4*Transcription factor, differentiationActivation[@mjw051C76]*Msx2*Inhibitor of osteoblast differentiationActivation[@mjw051C28]*Mab21L1*Transcriptional repressorActivation[@mjw051C28], [@mjw051C27]*Dlx5*Positive mediator of Bmp signallingRepression[@mjw051C28]*PPAR-γ*Activator of adipocyte differentiationActivation[@mjw051C6], [@mjw051C5]*MMP-9*Degrades extracellular matrixRepression[@mjw051C56]*MDM2*Ubiquitin E3 ligaseActivation[@mjw051C54]*Sox2*Transcription factor, stem cell pluripotencyActivation[@mjw051C7]*DLX3*Homeobox transcription factor, inhibitorActivation[@mjw051C2]*HRK*Pro-apoptoticActivation[@mjw051C2]Table 2The regulations of ELF4.RegulationRegulatory factorsEffectReferencesTranscriptionSP1Activation[@mjw051C29]TranscriptionE2F1Activation[@mjw051C71]TranscriptionHIF-1αActivation[@mjw051C68]Transcription/enhancerPU.1, FLI-1, ERGActivation[@mjw051C61]TranscriptionGFI1BRepression[@mjw051C61]PhosphorylationCYCLIN A/CDK2Restriction of ELF4 activity to G1 phase[@mjw051C45]PhosphorylationATM kinaseProtein degradation[@mjw051C52]PhosphorylationTBK1Activation[@mjw051C78]PhosphorylationMKK4/JNK1Activation[@mjw051C27]UbiquitinationSCF/SKP2Protein degradation[@mjw051C37]UbiquitinationMDM2Protein degradation[@mjw051C64]SUMOylationSUMO-1/-2Repression[@mjw051C67]**Interactions/fusionsPartners**Protein interactionPMLActivation[@mjw051C66], [@mjw051C69]Protein interactionSTINGActivation[@mjw051C78]Protein interactionRUNX2Repression, activation[@mjw051C28], [@mjw051C33]Protein interactionAML1BActivation[@mjw051C42]Protein interactionAML1/ETO fusion proteinRepression[@mjw051C42]Protein interactionWild-type and mutant nucleophosminRepression and activation, respectively[@mjw051C1]Translocation/fusionERGNot determined[@mjw051C47]Inversion/fusionBCORL1Repression[@mjw051C73]

![Functional, interacting, and modified residues of ELF4 protein. (**A**) ELF4 has 663 amino acid residues. Numbers are amino acid residues. P, phosphorylation; S, SUMOylation; Ub, ubiquitination; NLS, nuclear localization signal. (**B**) ELF4 interacts or is fused with various proteins at the indicated amino acid residues. AML1, PML, and STING proteins interact with ELF4. Fusions with ERG-1 and BCORL1 result from chromosomal translocation and inversion, respectively. Inset, fused regions of BCORL1 and ELF4. The C-terminal region of ELF4 (395−663 amino acids) is fused with most of BCORL1 (1−1618 amino acids). PRD, proline-rich domain; ANK, tandem ankryin repeats; NR boxes, nuclear receptor recruitment motifs. The indicated domains are not drawn to scale.](mjw051f01){#mjw051F1}

ELF4 in immunity {#mjw051s3}
================

One of the first elucidated roles of ELF4 was the activation of the immune-related molecules interleukin (IL)-3 and granulocyte macrophage-colony stimulating factor (GM-CSF) in myeloid and T cell lines ([@mjw051C46]). At the time that [@mjw051C46] reported the cloning of ELF4, our laboratory was also attempting to clone this gene (unpublished data). We found that in epithelial cells, ELF4 strongly activates the *lysozyme* gene, an antimicrobial protein that is important in host defence at mucosal surfaces and in leukocytes. Among the ETS factors tested such as ELF-1, ESE-1, ETS-1, ETS-2, and PEA-3, only ELF4 was able to upregulate the *lysozyme* promoter activity ([@mjw051C25]). Another antimicrobial molecule that is regulated by ELF4 is the human beta defensin 2 (HβD2). ELF4 binds to the promoter of *HβD2* to activate the gene in human lung adenocarcinoma cell line A549 ([@mjw051C39]). In hematopoietic cells, ELF4, but not other ETS factors, can activate *IL-8*, a CXC chemokine expressed in macrophage, epithelial, and endothelial cells ([@mjw051C23]). IL-8 is an important mediator of immune response by recruiting leukocytes to sites of infection.

A study on *Elf4*^*--/--*^ mice primarily revealed that ELF4 is essential in the development and function of NK and NK-T cells ([@mjw051C30]). *Elf4*^*--/--*^ NK cells are incapable of lysing tumour cell targets due to a defective *perforin* gene expression and minimal secretion of interferon (IFN)-γ. ELF4 binds to the *perforin* promoter and activates basal perforin transcription ([@mjw051C30]) (Figure [2](#mjw051F2){ref-type="fig"}A). A highly significant study done by Fikrig\'s group demonstrated that *Elf4*^*--/--*^ mice were more susceptible to West Nile virus infection, subsequently revealing a critical function of ELF4 in the induction of type I IFNs *Ifn-α* and *Ifn-β* ([@mjw051C78]). The C-terminal region of ELF4 (480−663 amino acids; Figure [1](#mjw051F1){ref-type="fig"}B) directly interacts with stimulator of interferon genes (STING), an adaptor protein in the type I IFN signalling pathway, and is recruited to the STING−MAVS−TBK1 complex (Figure [2](#mjw051F2){ref-type="fig"}B). This interaction activates ELF4 by phosphorylation at serine 331 residue, induces the nuclear translocation of ELF4, and results in the binding of ELF4 to IFN promoters. ELF4 stimulates IFN promoters in cooperation with the interferon regulatory factors IRF-3 and IRF-7 (Figure [2](#mjw051F2){ref-type="fig"}B). In addition, ELF4 is activated by virus infection ([@mjw051C78]). This work established ELF4 as a critical factor in type I IFN responses ([@mjw051C70]).

![The roles of ELF4. (**A**) ELF4 is necessary for the development and function of NK cells. (**B**) During viral infection, ELF4 interacts with the immune signalling adaptor STING and is recruited to the STING−MAVS−TBK1 complex. TBK1 phosphorylates ELF4, resulting in the translocation of ELF4 to the nucleus where it binds to and activates type I IFN promoters cooperatively with IRF-3 and IRF-7. (**C**) ELF4 inhibits RUNX2-mediated and BMP-2 signalling-dependent differentiation of osteoblasts. ELF4 enhances PPAR-γ-induced differentiation of adipocytes. (**D**) ELF4 drives hematopoietic stem cells (HSCs) from quiescent state (G0) to G1 phase and promotes the cell cycle progression from G1 to S phase. (**E**) ELF4 and P53 transcriptionally activate MDM2, which is the E3 ligase of both ELF4 and P53.](mjw051f02){#mjw051F2}

In another study, Lacorazza\'s group clearly revealed the modulatory role of ELF4 in the proliferation of naïve CD8^+^ T cells and the homing of T cells by activating the zinc-finger transcription factors Krüppel-like factor (*Klf*)-*4* and *Klf2*. *Elf4*^*--/--*^ mice displayed higher steady-state proliferation rate of naïve CD8^+^ T cells, deregulated T cell population expansion after immunization, and redistribution of cells to non-lymphoid tissues, suggesting the importance of ELF4 in controlling the homoeostasis, activation, and homing of T cells ([@mjw051C76]). Consistent with these deficiencies in T cell function in *Elf4*^*--/--*^ mice, lower number of effector memory CD8^+^ T cells was produced in the absence of *Elf4* during *Listeria monocytogenes* infection, indicating the importance of *Elf4* in the expansion of both central and effector memory CD8^+^ T cells ([@mjw051C41]). Importantly, [@mjw051C34] showed that the absence of ELF4 resulted in more severe disease phenotypes of experimental autoimmune encephalomyelitis in mice. *Elf4*^*--/--*^ mice had higher level of IL-17 due to enhanced Th17 differentiation of CD4^+^ T cells. This suggested that ELF4 is necessary in restricting the Th17 response to infection by limiting CD4^+^ T cell differentiation to Th17 lineage. Collectively, these studies demonstrated the importance of ELF4 in the regulation of adaptive and innate immunity.

The clinical significance of ELF4 in terms of its role in immunity is highlighted by the reports of Nelson\'s group showing that mutation in ELF4 may have caused the X-linked hypogammaglobulinemia with growth hormone deficiency (XLH-GHD), a rare immunodeficiency disorder ([@mjw051C62]). Patients affected with this disease carry a mutation of a base change at 1487 from T to C, resulting in a change at codon 369 from serine to proline ([@mjw051C63]). Although serine 369 had not been shown as a critical phosphorylation site in other studies ([@mjw051C45]; [@mjw051C37]), the authors hypothesized that a mutation in this site will interfere with ELF4 interaction with other proteins or its ability to bind to DNA, or the mutation may disrupt the proper folding of ELF4 protein ([@mjw051C63]). XLH-GHD patients present varied symptoms such as chronic infection, tissue inflammation, and arthritis, and share many other clinical features with the more common X-linked agammaglobulinemia (XLA), which is caused by mutations in the Bruton\'s tyrosine kinase (*BTK*) gene ([@mjw051C38]). It is interesting to note that a recent report showed that the severity of disease in patients with common variable immunodeficiency (CVID), including hypogammaglobulinemia, inversely correlated with the circulating NK cell count. The lower the number of circulating NK cells, the more severe the disease phenotypes ([@mjw051C13]). It is tempting to speculate that in these patients, the *ELF4* gene and/or protein is dysfunctional, leading to reduced NK cell function and the consequent immune defects. Further investigations on ELF4, especially the effects of ELF4 mutation on its function in immune response, and additional clinical data linking ELF4 mutation with human diseases will establish ELF4 as an important player in human immune defence.

ELF4 in development and differentiation {#mjw051s4}
=======================================

The members of the ETS family of transcription factors are well known for their functions in lineage development and cellular differentiation ([@mjw051C43]; [@mjw051C55]; [@mjw051C44]), and ELF4 is no exception. As mentioned above, ELF4 is necessary for the development of NK and NK-T cells, and has a growing significance in hematopoiesis ([@mjw051C31]). ELF4 has also been reported to exert a suppressive effect on osteogenic differentiation ([@mjw051C28]). *In vitro* studies revealed that ELF4 expression is highest in the early stage of differentiation of MC3T3-E1 cells ([@mjw051C28]), a murine osteogenic cell line capable of differentiating into osteoblasts. *Elf4* mRNA expression is downregulated by bone morphogenic protein-2 (BMP-2), and ELF4 in turn antagonizes the BMP-2 signalling. The ability of ELF4 to suppress bone formation is via interaction with RUNX2 protein ([@mjw051C28]), a molecule downstream of BMP-2 and critical regulator of osteoblast differentiation ([@mjw051C51]). Interaction of ELF4 with RUNX2 prevents RUNX2 from binding to osteoblast-specific element OSE2 present in *osteocalcin* gene. In addition, ELF4 inhibits the transcription of *Dlx5*, an effector of BMP-2 for bone formation, and induces the transcription of *Msx2*, a negative regulator of osteoblast differentiation ([@mjw051C28]). The *in vitro* data were verified by *in vivo* studies of transgenic mice overexpressing *Elf4* specifically in osteoblasts under the control of the *Col1α1* promoter (*Col1α1*-*Elf4* Tg mice). These mice displayed osteopenia in vertebrae, more porous cortical bone, and fewer trabeculae in long bones due to the suppression of osteoblast maturation and increase of osteoclast differentiation induced by ELF4 ([@mjw051C58]). Collectively, these findings demonstrated that ELF4 inhibits bone formation (Figure [2](#mjw051F2){ref-type="fig"}C). Interestingly, the *Col1α1*-*Elf4* Tg mice have high bone marrow adiposity while displaying low bone mass ([@mjw051C6]). Both osteoblasts and adipocytes are derived from mesenchymal stem cells, and by having a shared progenitor there is a degree of plasticity between these cell lineages ([@mjw051C8]). Primary bone marrow cells derived from *Col1α1*-*Elf4* Tg mice have higher potential for adipogenic differentiation compared with that from wild-type mice. The overexpression of *Elf4* also enhanced the adipogenic differentiation of MC3T3-E1 cells ([@mjw051C6]). ELF4 binds to and transactivates the peroxisome proliferator-activated receptor γ (PPARγ), a crucial factor that drives adipocyte differentiation. Upregulation of PPARγ activity results in bone loss and an increase in bone marrow adiposity ([@mjw051C80]). Therefore, ELF4 induces adipogenic differentiation while dampening bone formation by suppressing the factors involved in osteoblast formation and activating the factors necessary for adipocyte differentiation ([@mjw051C5]) (Figure [2](#mjw051F2){ref-type="fig"}C). Despite the clear presentation of the role of ELF4 in osteogenic and adipogenic differentiation and the genes it affects, some questions remain, such as how is ELF4 regulated and how deeply it is involved in the cellular fate decision between adipogenesis and osteogenesis. How is ELF4 activated to generate its downstream effects, and at what point in the cascade downstream of mesenchyme does ELF4 begin to get involved? Importantly, does it participate in the pathogenesis and progression of bone diseases such as osteoporosis? Is it involved in metabolic disease? The answers to these questions could prove to be crucial not only to clarify the depth of the involvement of ELF4 in mesenchymal lineage differentiation, but also to understand its role in health and disease.

ELF4 in cell homoeostasis {#mjw051s5}
=========================

It has been documented that ELF4 drives the cell cycle progression from G1 to S phase ([@mjw051C45]) (Figure [2](#mjw051F2){ref-type="fig"}D). This is one of the earliest known functions of ELF4, and is in line with the role of ETS transcription family members in regulating cell cycle and cell proliferation ([@mjw051C15]; [@mjw051C40]). The sequential phosphorylation, ubiquitination, and degradation of ELF4 that restrict the activity of ELF4 in the G1 phase lead to the transition from G1 to S phase and promote cell proliferation ([@mjw051C37]). But while the involvement of ELF4 in G1/S phase progression was clearly elucidated, the underlying mechanism of how ELF4 exerts this effect is less clear. Also lacking is the information of the cell cycle-related genes that are targeted by ELF4 to induce this phase transition. Consistent with being able to regulate the cell cycle progression, ELF4 facilitates the entry of quiescent (G0) HSCs into the cell cycle and induces HSC proliferation ([@mjw051C32]) (Figure [2](#mjw051F2){ref-type="fig"}D). *Elf4*^*--/--*^ HSCs have increased population residing in the G0 phase compared with wild-type counterparts. The quiescent state of HSCs is necessary to preserve the genomic integrity of the cells over its lifetime and protect the stem cell pool against stress and injury. Cell quiescence is a reversible, 'poised' state of the cells that allows for rapid activation when expansion and differentiation are needed ([@mjw051C10]). ELF4 is one of the factors that promote the shift of HSCs from quiescent to an active, cycling state. Moreover, [@mjw051C32] showed that *Elf4*^*--/--*^ HSCs are resistant to the effects of chemotherapy and radiation, suggesting that ELF4 may also regulate the quiescence and chemoresistance in leukaemia stem cells. ELF4 was also shown to control the quiescence of endothelial cells ([@mjw051C60]). The ability of ELF4 to modulate HSC quiescence is partly due to its suppressive effect on p53, which maintains HSC quiescence, via the transcriptional activation of the p53 E3 ligase MDM2 ([@mjw051C36]; [@mjw051C54]). That ELF4 influences the activity of the tumour suppressor p53, thereby affecting cell cycle and cellular state and fate, indicates the involvement of ELF4 in maintaining the homoeostasis of cells (Figure [2](#mjw051F2){ref-type="fig"}E). Its absence could result in the imbalance of cell proliferation and quiescence.

ELF4 is implicated in the cellular DNA damage response to γ-irradiation ([@mjw051C52]). The loss of ELF4 hastens the repair of damaged DNA by abrogating DNA damage response but consequently, this gives rise to radio-resistant cell phenotype. In *Elf4*^*--/--*^ cells, the activity of p53 was dampened in response to γ-irradiation, and less apoptotic cells were detected, indicating that ELF4 is necessary for inducing p53 function under γ-irradiation condition ([@mjw051C52]). How ELF4 regulates p53 activation during γ-irradiation is less clear, but the dual nature of ELF4 in terms of its relation to p53 (inhibitory and activating) is intriguing and needs further investigation to understand the role of ELF4 in normal and stressed cells.

ELF4 in cancer {#mjw051s6}
==============

Aberrant interaction of ELF4 with the oncofusion protein acute myeloid leukaemia (AML1)/ETO is one of the indications of the involvement of ELF4 in cancer ([@mjw051C42]). ELF4 and AML1 interaction occurs at the N-terminal portion of ELF4 (Figure [1](#mjw051F1){ref-type="fig"}B) and the runt homology domain of AML1 proteins. AML1B interaction with ELF4 enhances the transcriptional activity of ELF4. However, the oncoprotein AML1/ETO−ELF4 interaction abolished the transactivating ability of ELF4. This implies that interference of ELF4 activity and function by this aberrant interaction may partly contribute to the dysregulation of myeloid differentiation and subsequent pathogenesis of t(8;21) AML ([@mjw051C42]). A chromosomal translocation in AML involving ELF4 was characterized in a patient wherein ELF4 was fused with another ETS transcription factor, ERG-1 ([@mjw051C47]). This rare chromosomal translocation t(Xq25−26;21q22) occurs within intron 2 of ELF4 and intron 1 of ERG-1, resulting in the fusion of exon 2 of ELF4 and exon 2 of ERG-1. The N-terminal region of ELF4 (amino acid residues 1−25; Figure [1](#mjw051F1){ref-type="fig"}B) was predicted to fuse with ERG-1. Although the function of this fusion protein has not been characterized, it was noted that because the *ELF4* promoter drives the ELF4−ERG fusion, the pattern of expression of this fusion protein would be similar to ELF4. However, the oncofusion is composed predominantly of amino acids from ERG-1 C-terminus, pointing to the possibility that the fusion protein would have the function and activity of ERG including its interactions with other proteins ([@mjw051C47]). How exactly ELF4 interferes with the normal roles of ERG-1 in this setting (and *vice versa*) is still unclear. [@mjw051C53] had emphasized that ELF4 and ERG could act as oncogenes. Indeed, the high level of ELF4 in the FAB subtype of AML correlated with poor prognosis in AML patients ([@mjw051C17]). It has also been shown that while the wild-type nucleophosmin (NPM1), a nucleolar phosphoprotein, interacts with ELF4 and inhibits its activity, mutant NPM1 does not interact with ELF4, which may result in increased ELF4 transactivation potential ([@mjw051C1]). Importantly, NPM1 is mutated in 50% of AML patients with normal karyotype ([@mjw051C14]).

The association of ELF4 with cancer has been reported not only in hematopoietic transformation, but also in solid tumours. A fusion transcript of *BCORL1−ELF4* was found by parallel sequencing of primary hepatitis C virus (HCV)-positive hepatocellular carcinoma derived from a patient ([@mjw051C73]). BCORL1 is a transcriptional co-repressor that associates with class II histone deacetylase and CtBP1. Interestingly, BCORL1 is recurrently mutated in AML ([@mjw051C72]). The fusion protein BCORL1−ELF4 arose from the combination of exons 1−11 of BCORL1 and exon 8 of ELF4 through intra-chromosomal inversion (Xq25 and 11q12). BCORL1−ELF4 has drastically reduced repression activity compared with wild-type BCORL1 protein ([@mjw051C73]), while ELF4 C-terminus, which is the ELF4 fragment fused to BCORL1 (Figure [1](#mjw051F1){ref-type="fig"}B, inset), has even lower repressor activity. The transcriptional-activation domain and DNA-binding domain of ELF4 reside in the N-terminus (residues 1−86) and at residues 207−291, respectively ([@mjw051C46]; [@mjw051C65]). The C-terminal region of ELF4 is necessary for its interaction with other proteins ([@mjw051C69]). This fusion may interfere with the repressor activity of BCORL1. But how significantly it contributes to the HCV-positive hepatic carcinogenesis remains to be determined, because there is a total of 22 validated chromosomal rearrangements in the examined tumour tissue ([@mjw051C73]), and tumour development is a complex process that involves myriad pathways and numerous proteins.

ELF4 is highly expressed in primary human ovarian tumours and ovarian cell lines, although there was no correlation of ELF4 expression with tumour stage, grade, and patient survival ([@mjw051C77]). The knockdown of ELF4 suppressed the malignant potential of ovarian cancer cells, indicating a role of ELF4 in promoting tumorigenic traits ([@mjw051C77]). ELF4 has also been implicated in promoting the stem-like characteristic in gliomas due to the ability of ELF4 to activate Sox2 ([@mjw051C7]), which is one of the transcription factors necessary to maintain stem cell traits. It was shown that ELF4 expression level is significantly higher in human gliomas compared with non-tumour brain tissue, and that *Elf4*^*--/--*^ mice have impaired neurosphere formation and slower growth of gliomas ([@mjw051C7]). One proposed mechanism for the oncogenic effect of ELF4 is its potential to activate MDM2 ([@mjw051C54]), the E3 ligase of the tumour suppressor p53. ELF4 binds to and activates the *MDM2* promoter. Furthermore, ELF4 can inhibit the oncogene-induced activation of p16 ([@mjw051C54]), a modulator of cell cycle. That ELF4 can drive cell cycle progression may also be a factor in its ability to induce aberrant proliferation under certain cellular conditions.

In contrast to several works describing ELF4 as an oncogenic protein, a number of studies showed that ELF4 could act as tumour suppressor in epithelial tissues. [@mjw051C56] first determined that ELF4 suppressed the growth of lung adenocarcinoma in nude mice injected with lung adenocarcinoma A549 cells. ELF4 expression is downregulated in a panel of cancer cell lines, and the overexpression of ELF4 in A549 cells inhibited the growth and invasiveness of A549 cells. ELF4 exerted its effect most likely via the inhibition of matrix metalloproteinase (MMP)-9 and IL-8. But how ELF4 suppresses MMP-9 and IL-8 expression was not investigated ([@mjw051C56]). Genomic profiling of prostate tumour initiating cells or 'prostatospheres' revealed that *ELF4* gene was downregulated in these cells ([@mjw051C12]). Interestingly, in a recent study, [@mjw051C4] was able to generate a murine model of multiple myeloma in *Elf4*-deficient hypomorphic-Rad50 mutant mice (*Elf4*^*--/--*^Rad50^s/s^). *ELF4* deficiency ameliorated the hematopoietic failure in Rad50^s/s^ mice, but surprisingly, 70% of these mice developed plasma cell neoplasms or multiple myeloma. These mice had abnormal proliferation of plasma cells, increased production of monoclonal sera, progressive anaemia, and osteoporosis ([@mjw051C4]). These phenotypes indicate that ELF4 is critically involved in the proper regulation of not only the myeloid cells but also cells of the lymphoid lineage. In a recent study by [@mjw051C2], ELF4 was demonstrated to be a tumour suppressor in a variety of tumour cell lines. Forced expression of wild-type ELF4 inhibited the proliferation of cancer cells, but mutant ELF4 (L211M), whose DNA-binding potential (and thus, its transactivation capacity) is lost, had no anti-proliferative effect ([@mjw051C2]). The BCORL1−ELF4 fusion protein, which had significant attenuation in its transactivation capacity compared to wild-type ELF4, was also unable to inhibit proliferation. Induction of wild-type ELF4 expression resulted in more tumour cells residing in the G0−G1 phase and less in the S phase, an observation that is not consistent with previously known function of ELF4 in promoting the cell cycle to the S phase ([@mjw051C37]). By genome-wide screening for binding sites of ELF4, it was revealed that ELF4 targets the genes associated with anti-proliferation, such as *DLX3* and *HRK* ([@mjw051C2]). This study clearly delineated the anti-tumour function of ELF4.

Considering these findings together, the question of how we reconcile the contrasting roles of ELF4 arises. Because *Elf4*^*--/--*^ mice have defective NK and NK-T cells that are incapable of lysing tumour targets, it is not surprising that ELF4 loss of function may generate an altered immune surveillance, resulting in a cellular environment that predisposes towards aberrant cell growth. *Elf4*^*--/--*^ mice do not spontaneously develop tumours ([@mjw051C30]), so that ELF4 may not be considered a *bona fide* tumour suppressor. But its dysregulated expression and function, by overexpression, silencing, and/or chromosomal translocation, could compromise the balance between cell proliferation, differentiation, quiescence, and death. More than 40 mutations of ELF4 protein, distributed throughout the protein structure, have been found in human cancers ([@mjw051C2]). How these mutations affect the function of ELF4 in relation to cell fate remains to be elucidated. It could be that some of these mutations confer a pro-tumorigenic effect while some anti-tumorigenic, others may silence ELF4 or over-activate it, and the final effect and contribution of ELF4 towards the cell fate will depend on environmental cues and cellular context. By itself, ELF4 may not be strictly a tumour suppressor or an oncogene, rather it is a molecule that is a critical player in cellular homoeostasis, and a disruption of its functions creates a milieu that makes cells more vulnerable to cellular insults.

Transcriptional regulation of ELF4 {#mjw051s7}
==================================

To gain insight into how *ELF4* transcription is regulated, we first cloned the 2-kb upstream of the transcription start site. We characterized the *ELF4* promoter as being responsive to the transcription factor SP1. SP1 binds to the *ELF4* promoter and induces *ELF4* activity ([@mjw051C29]). We also found that *ELF4* transcription is activated by the transcription factor E2F1 ([@mjw051C71]). The specific binding of E2F1 to *ELF4* proximal promoter (\~200 bp upstream of start site) was abrogated by the interaction between E2F1 and p53 (Figure [3](#mjw051F3){ref-type="fig"}A). In doxorubicin-induced senescent cells, wherein p53 is activated, p53 directly interacts with E2F1, sequestering E2F1 away from the *ELF4* promoter, and preventing E2F1 binding to consensus site. This is one way in which p53 negatively regulates *ELF4* ([@mjw051C71]). *ELF4* is also transcriptionally upregulated by hypoxia-inducible factor-1α (HIF-1α) ([@mjw051C68]) (Figure [3](#mjw051F3){ref-type="fig"}A). Under hypoxic condition, activated HIF-1α binds to the *ELF4* promoter and activates *ELF4* transcription, which leads to an increase in ELF4 function ([@mjw051C68]). These investigations of *ELF4* transcriptional regulation were carried out mainly in epithelial cells. Whether *ELF4* is similarly regulated by these transcription factors in hematopoietic tissues remains to be elucidated.

![The regulations of ELF4. (**A**) The transcriptional regulation of ELF4. ELF4 is targeted by various transcription factors in its promoter and enhancer regions. (**B**) The post-translational regulations of ELF4. ELF4 protein is subject to modifications that lead to its activation, dampening of activity (inhibition), or degradation. Phosphorylation by ATM kinase leads to the degradation of ELF4 (broken arrow).](mjw051f03){#mjw051F3}

[@mjw051C61] analysed the transcriptional control of *ELF4* in hematopoietic and endothelial cells and identified five distinct regulatory regions, including three promoter regions and two enhancer regions, in the *ELF4* locus. These active promoter and enhancer regions, characterized by chromatin modification of trimethylated lysine 4 of histone 3 (H3Me3K4), were mapped to kb −39, −30, and −2 for promoter regions and −16 and −10 for enhancer regions in hematopoietic and endothelial cells ([@mjw051C61]). The enhancer region contains ETS sites wherein the ETS factors PU.1, ERG, and FLI-1 bind and induce *ELF4* activity (Figure [3](#mjw051F3){ref-type="fig"}A). Importantly, the study revealed that *ELF4* is suppressed by the transcriptional repressor GFI1B, which binds to the *ELF4* promoter at −30 kb, and this repression is necessary for the maturation of erythroid cells ([@mjw051C61]). This makes *ELF4* a key target of GFI1B, which is an important repressor during erythropoiesis ([@mjw051C19]), although little is known about other genes that GFIB has to suppress. Interestingly, GFI-1, the close relative of GFI1B, is induced by p53 to promote HSC quiescence, whereas *ELF4* can inhibit p53 ([@mjw051C36]). Piecing together these findings generates a network of transcription factors that incorporates *ELF4* in the regulation of HSCs. Although *ELF4* is important in driving stem cells out of quiescence into expansion, its presence may prevent erythroid differentiation. Thus, tight regulation of *ELF4* expression and function through various factors is necessary.

Post-translational regulation of ELF4 {#mjw051s8}
=====================================

ELF4 is a substrate for phosphorylation of the cyclin-dependent kinase (CDK) cyclin A1/Cdk2 and cyclin D/Cdk4 at the serine and threonine residues at 641−657 amino acids. Following this post-translational modification, ELF4 is ubiquitinated by the E3 ubiquitin ligase SCF/SKP2 ([@mjw051C45]; [@mjw051C37]) (Figure [3](#mjw051F3){ref-type="fig"}B). These modifications limit the activity of ELF4 in the G1 phase of cell cycle. Non-phosphorylatable ELF4 mutant cannot be ubiquitinated by SCF/SKP2, underscoring the sequential post-translational modifications as necessary for ELF4 degradation ([@mjw051C37]). In addition to SCF/SKP2, MDM2 is also an E3 ubiquitin ligase that targets ELF4 for degradation regardless of the phosphorylation status of ELF4 ([@mjw051C64]). The overexpression of MDM2 decreased the protein expression level of ELF4, while MDM2 knockdown increased ELF4 expression. Because ELF4 transcriptionally activates *MDM2*, this provides a critical self-regulatory feedback mechanism of ELF4 regulation ([@mjw051C54]; [@mjw051C64]) similar to that of p53 and MDM2. The MDM2-induced decrease of ELF4 protein can occur in the absence of p53, indicating a p53-independent mechanism for ELF4 autoregulatory inhibition ([@mjw051C64]) (Figures [2](#mjw051F2){ref-type="fig"}E and [3](#mjw051F3){ref-type="fig"}B). However, the presence of p53 enhanced the suppressive effect of MDM2, suggesting that p53 may also participate in the degradation of ELF4 through its ability to transcriptionally activate MDM2. This triad of p53−MDM2−ELF4 provides an intriguing interplay of reciprocal negative regulation between p53 and ELF4 via MDM2 ([@mjw051C64]) (Figure [2](#mjw051F2){ref-type="fig"}E). In response to DNA damage, ELF4 is phosphorylated by the ATM kinase at T70, S369, and S472 residues, leading to the degradation of ELF4 ([@mjw051C52]). ELF4 is also phosphorylated by the MKK4/JNK signalling pathway at amino acid residue 641 to enhance the transactivating function of ELF4 on the *MAB21L1* promoter in the context of parathyroid hormone-induced bone resorption ([@mjw051C27]).

The conjugation of small ubiquitin-related modifier (SUMO) to ELF4 protein also occurs as another post-translational modification for ELF4 (Figure [3](#mjw051F3){ref-type="fig"}B) ([@mjw051C67]). Specifically, lysine 657 in the C-terminal region of ELF4 is conjugated to SUMO. The consequence of this modification is the suppression of the transactivating function of ELF4 ([@mjw051C67]). Chromatin immunoprecipitation assay revealed that SUMO-conjugated ELF4 had diminished recruitment to the *lysozyme* promoter, which is one of the ELF4 target genes. In addition to phosphorylation, ubiquitination, and sumoylation, ELF4 may also be acetylated, being lysine-rich with numerous lysine residues that are predicted to be acetylated (unpublished data). The post-translational changes that ELF4 can undergo are important, because these modifications clearly affect the functions and activities of ELF4 (Figure [3](#mjw051F3){ref-type="fig"}B), and thereby affecting the signalling pathways downstream of ELF4. Not only protein modification, but also protein−protein interaction has been reported for ELF4. Promyelocytic leukaemia protein (PML) interacts with ELF4 at the C-terminal region (Figure [1](#mjw051F1){ref-type="fig"}B), and induces the localization of ELF4 to PML nuclear bodies. This leads to the enhancement of ELF4 transcriptional function on the *lysozyme* and *HβD2* promoters ([@mjw051C66], [@mjw051C69]). But whether the ELF4−PML interaction has physiological or pathophysiological relevance is unknown. Further discoveries of ELF4 interaction with other proteins, such as AML1 ([@mjw051C42]) and nucleophosmin ([@mjw051C1]) among others, could provide better understanding of how functions of ELF4 are modulated by proteins that ELF4 comes in contact with.

Concluding remarks {#mjw051s9}
==================

As a transcription factor, ELF4 may be able to activate or repress its target genes depending on certain cellular context and conditions. The majority of the works on ELF4 had demonstrated that ELF4 is a strong transcriptional activator, and only a couple of studies had shown ELF4 as a repressor. While the activating function of ELF4 has been mechanistically explained and proved through deletion studies of its transactivation domain, the mechanism of how ELF4 exerts its repressing capability has not been clearly elucidated. It is possible that ELF4 can recruit certain co-repressors to the promoter region of its target genes. Future studies may clarify this possibility.

As a protein that is part of a broader network, ELF4 acts in conjunction with its partner proteins. An aberration of ELF4 activity due to mutation, cell damaging stimuli, or dysregulated cellular signalling upstream of ELF4 could result in the loss of cellular homoeostasis, which may lead to a diseased cell state. The lessons learned about the roles and regulations of ELF4 may be applied to other ETS transcription factors as well and could open an avenue towards better understanding and strategies of therapies for bone diseases, immunity, metabolism, and cancer.
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